176 results
P20: Evaluating xanomeline and trospium as a treatment for psychosis associated with Alzheimer’s disease: design of the phase 3, ADEPT-1, relapse prevention study
-
- Journal:
- International Psychogeriatrics / Volume 36 / Issue S1 / September 2024
- Published online by Cambridge University Press:
- 27 November 2024, pp. 93-94
-
- Article
-
- You have access
- Export citation
Advances in Alzheimer’s Disease Therapeutics: A Global Perspective
-
- Journal:
- International Psychogeriatrics / Volume 36 / Issue S1 / September 2024
- Published online by Cambridge University Press:
- 27 November 2024, p. 4
-
- Article
-
- You have access
- Export citation
P19: Design of ADEPT-2, a phase 3, parallel group study to evaluate xanomeline and trospium as a treatment for psychosis associated with Alzheimer’s disease dementia
-
- Journal:
- International Psychogeriatrics / Volume 36 / Issue S1 / September 2024
- Published online by Cambridge University Press:
- 27 November 2024, pp. 128-129
-
- Article
-
- You have access
- Export citation
An overview of the pathophysiology of agitation in Alzheimer’s dementia with a focus on neurotransmitters and circuits
-
- Journal:
- CNS Spectrums / Volume 29 / Issue 5 / October 2024
- Published online by Cambridge University Press:
- 23 October 2024, pp. 316-325
-
- Article
-
- You have access
- Open access
- HTML
- Export citation
97 Exploring Urban-Rural Disparities in Alzheimer’s disease: Clinical characterization of a southern Nevada cohort
-
- Journal:
- Journal of the International Neuropsychological Society / Volume 29 / Issue s1 / November 2023
- Published online by Cambridge University Press:
- 21 December 2023, pp. 397-399
-
- Article
-
- You have access
- Export citation
4 Risk Factor and Biomarker Correlates of FLAIR White Matter Hyperintensities in Former American Football Players
-
- Journal:
- Journal of the International Neuropsychological Society / Volume 29 / Issue s1 / November 2023
- Published online by Cambridge University Press:
- 21 December 2023, pp. 608-610
-
- Article
-
- You have access
- Export citation
Rarer dementias, limited options, and unaddressed needs: Commentary on “A Mixed Methods Evaluation of a Programme Exploring Pre-death Grief and Loss for Carers of People with Rarer Dementias,” by Stevens-Neck et al.
-
- Journal:
- International Psychogeriatrics / Volume 36 / Issue 6 / June 2024
- Published online by Cambridge University Press:
- 04 May 2023, pp. 451-454
-
- Article
-
- You have access
- HTML
- Export citation
Agitation in cognitive disorders: Progress in the International Psychogeriatric Association consensus clinical and research definition
-
- Journal:
- International Psychogeriatrics / Volume 36 / Issue 4 / April 2024
- Published online by Cambridge University Press:
- 07 March 2023, pp. 238-250
-
- Article
-
- You have access
- Open access
- HTML
- Export citation
Reduction and prevention of agitation in persons with neurocognitive disorders: an international psychogeriatric association consensus algorithm
-
- Journal:
- International Psychogeriatrics / Volume 36 / Issue 4 / April 2024
- Published online by Cambridge University Press:
- 06 March 2023, pp. 251-262
-
- Article
-
- You have access
- Open access
- HTML
- Export citation
Open innovation: the key to advancing brain health
-
- Journal:
- CNS Spectrums / Volume 28 / Issue 4 / August 2023
- Published online by Cambridge University Press:
- 29 July 2022, pp. 392-394
-
- Article
-
- You have access
- HTML
- Export citation
Section 3 - Alzheimer’s Disease Clinical Trials
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 135-360
-
- Chapter
- Export citation
Section 2 - Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 73-134
-
- Chapter
- Export citation
Section 5 - Academic Drug-Development Programs
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 429-454
-
- Chapter
- Export citation
Dedication
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp v-vi
-
- Chapter
- Export citation
Index
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 544-554
-
- Chapter
- Export citation
6 - Artificial Intelligence in Alzheimer’s Drug Discovery
- from Section 1 - Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
-
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 62-72
-
- Chapter
- Export citation
Foreword
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp xix-xix
-
- Chapter
- Export citation
Section 6 - Public–Private Partnerships in Alzheimer’s Disease Drug Development
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 455-464
-
- Chapter
- Export citation
1 - Alzheimer’s Disease Drug Development: A Research and Development Ecosystem
- from Section 1 - Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
-
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp 1-24
-
- Chapter
- Export citation
Contents
-
- Book:
- Alzheimer's Disease Drug Development
- Published online:
- 03 March 2022
- Print publication:
- 31 March 2022, pp vii-x
-
- Chapter
- Export citation